{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:47:09Z","timestamp":1794329229112,"version":"4.9.0"},"reference-count":46,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>Treatment with immune checkpoint inhibitors (ICIs) has shown clinical benefit for a wide range of cancer types. The neutrophil-to-lymphocyte ratio (NLR) reportedly correlates with survival time or progression-free survival in patients treated with ICIs. However, NLR has not yet been assessed in patients with brain metastases (BMs) receiving stereotactic radiosurgery (SRS) combined with concurrent ICIs. The authors investigated the predictive impact of NLR on the survival data of patients with BMs who received SRS with concurrent ICIs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>The clinical records of patients who had undergone SRS with concurrent ICIs for BMs between January 2015 and August 2023 were retrospectively analyzed. NLR was calculated using the data obtained from the last examination prior to SRS. The optimal NLR cutoff value was identified by receiver operating characteristic (ROC) curve analysis for time-to-event data (overall survival [OS] \u2264 18 months). OS and intracranial disease progression-free survival (IC-PFS) rates were compared between the two NLR groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Of the 185 eligible patients included, 132 were male. The median (IQR) patient age was 69 (61\u201375) years. The primary cancers were lung, genitourinary, skin, breast, gastrointestinal, and others in 132, 23, 22, 2, 2, and 4 patients, respectively. The post-SRS median OS and IC-PFS times for the entire cohort were 18.4 (95% CI 14.0\u201323.1) months and 9.2 (95% CI 6.9\u201310.8) months, respectively. ROC curve analysis identified the optimal NLR cutoff value for 18-month OS to be 5.0 (area under the curve 0.64, Youden index 0.31). Kaplan-Meier analysis revealed that patients with high NLR (&gt; 5) had a significantly shorter OS (median survival time 10.9 months for 48 patients vs 22.2 months for 137 patients, HR 2.0, 95% CI 1.3\u20133.0, p &lt; 0.001). Similarly, a significant difference in median IC-PFS was noted: 4.8 months with high NLR versus 10.7 months with low NLR (HR 1.7, 95% CI 1.2\u20132.5, p = 0.003).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CONCLUSIONS<\/jats:title>\n<jats:p>The authors found elevated pre-SRS NLR (&gt; 5) to be associated with shorter OS and IC-PFS after SRS with concurrent ICIs for BMs. NLR is a simple, cost-effective, and widely accessible biomarker, which can thus be used for managing patients with BMs receiving SRS concurrently with ICIs. Further investigation in other large datasets is, however, required to validate these findings.<\/jats:p>\n<\/jats:sec>","DOI":"10.3171\/2024.5.jns24259","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T01:29:19Z","timestamp":1724462959000},"page":"1-10","source":"Crossref","is-referenced-by-count":3,"title":["Pre\u2013stereotactic radiosurgery neutrophil-to-lymphocyte ratio predicts post\u2013stereotactic radiosurgery survival of patients with brain metastases concurrently treated with immune checkpoint inhibitors"],"prefix":"10.3171","author":[{"given":"Shoji","family":"Yomo","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology, Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto City, Nagano Prefecture, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyota","family":"Oda","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto City, Nagano Prefecture, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Oguchi","sequence":"additional","affiliation":[{"name":"Positron Imaging Center, Aizawa Hospital, Matsumoto City, Nagano Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"2","key":"b1","series-title":"N Engl J Med","first-page":"122","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok JD","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK,  Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122\u2013133."},{"issue":"21","key":"b2","series-title":"N Engl J Med","first-page":"2018","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon EB","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R,  Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u20132028."},{"issue":"24","key":"b3","series-title":"N Engl J Med","first-page":"2342","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia SJ","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D,  Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u20132350."},{"issue":"23","key":"b4","series-title":"N Engl J Med","first-page":"2220","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A,  First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20132229."},{"issue":"14","key":"b5","series-title":"N Engl J Med","first-page":"1277","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer RJ","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF,  Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u20131290."},{"issue":"21","key":"b6","series-title":"N Engl J Med","first-page":"2020","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann MD","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R,  Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u20132031."},{"issue":"7","key":"b7","series-title":"Lancet Oncol","first-page":"976","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg SB","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A,  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976\u2013983."},{"issue":"8","key":"b8","series-title":"N Engl J Med","first-page":"722","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi HA","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A,  Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722\u2013730."},{"issue":"23","key":"b9","series-title":"J Clin Oncol","first-page":"2008","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study","volume":"37","author":"Flippot R","year":"2019","unstructured":"Flippot R, Dalban C, Laguerre B,  Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. J Clin Oncol. 2019;37(23):2008\u20132016."},{"issue":"5","key":"b10","series-title":"Lancet Oncol","first-page":"655","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg SB","year":"2020","unstructured":"Goldberg SB, Schalper KA, Gettinger SN,  Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655\u2013663."},{"issue":"4","key":"b11","series-title":"Int J Radiat Oncol Biol Phys","first-page":"916","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"100","author":"Chen L","year":"2018","unstructured":"Chen L, Douglass J, Kleinberg L,  Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(4):916\u2013925."},{"key":"b12","series-title":"Radiother Oncol","first-page":"104","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer EJ","year":"2019","unstructured":"Lehrer EJ, Peterson J, Brown PD,  Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol. 2019;130:104\u2013112."},{"issue":"6","key":"b13","series-title":"J Neurosurg","first-page":"1591","article-title":"Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores","volume":"138","author":"Yomo S","year":"2022","unstructured":"Yomo S, Oda K, Oguchi K. Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores. J Neurosurg. 2022;138(6):1591\u20131599."},{"issue":"6","key":"b14","series-title":"J Neurosurg","first-page":"1628","article-title":"Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis","volume":"139","author":"Yomo S","year":"2023","unstructured":"Yomo S, Oda K, Oguchi K. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis. J Neurosurg. 2023;139(6):1628\u20131637."},{"key":"b15","series-title":"Lung Cancer","first-page":"120","article-title":"Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: a retrospective analysis of 133 consecutive patients","volume":"119","author":"Yomo S","year":"2018","unstructured":"Yomo S, Oda K. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: a retrospective analysis of 133 consecutive patients. Lung Cancer. 2018;119:120\u2013126."},{"issue":"1","key":"b16","series-title":"J Neurooncol","first-page":"151","article-title":"The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI)","volume":"145","author":"Yomo S","year":"2019","unstructured":"Yomo S, Serizawa T, Yamamoto M,  The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI). J Neurooncol. 2019;145(1):151\u2013157."},{"issue":"4","key":"b17","series-title":"Mol Cancer Ther","first-page":"847","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel SP","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u2013856."},{"issue":"6349","key":"b18","series-title":"Science","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","unstructured":"Le DT, Durham JN, Smith KN,  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u2013413."},{"issue":"2","key":"b19","series-title":"Nat Genet","first-page":"202","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein RM","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN,  Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u2013206."},{"issue":"1","key":"b20","series-title":"Crit Rev Oncol Hematol","first-page":"218","article-title":"The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer","volume":"88","author":"Guthrie GJ","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218\u2013230."},{"issue":"6","key":"b21","series-title":"J Natl Cancer Inst","first-page":"dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton AJ","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B,  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124."},{"issue":"2","key":"b22","series-title":"J Neurosurg","first-page":"433","article-title":"Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis","volume":"127","author":"Mitsuya K","year":"2017","unstructured":"Mitsuya K, Nakasu Y, Kurakane T, Hayashi N, Harada H, Nozaki K. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis. J Neurosurg. 2017;127(2):433\u2013437."},{"issue":"4","key":"b23","series-title":"J Surg Oncol","first-page":"470","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review","volume":"115","author":"Haram A","year":"2017","unstructured":"Haram A, Boland MR, Kelly ME, Bolger JC, Waldron RM, Kerin MJ. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review. J Surg Oncol. 2017;115(4):470\u2013479."},{"key":"b24","series-title":"Cancer Treat Rev","first-page":"1","article-title":"Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies","volume":"58","author":"Mei Z","year":"2017","unstructured":"Mei Z, Shi L, Wang B,  Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017;58:1\u201313."},{"issue":"3","key":"b25","series-title":"J Neurooncol","first-page":"691","article-title":"Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio is a predictor of the prognosis for brain metastases","volume":"147","author":"Zhang L","year":"2020","unstructured":"Zhang L, Hu Y, Chen W, Tian Y, Xie Y, Chen J. Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio is a predictor of the prognosis for brain metastases. J Neurooncol. 2020;147(3):691\u2013700."},{"issue":"6","key":"b26","series-title":"Clin Transl Oncol","first-page":"1185","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy","volume":"23","author":"Vi\u00f1al D","year":"2021","unstructured":"Vi\u00f1al D, Gutierrez-Sainz L, Martinez D,  Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. Clin Transl Oncol. 2021;23(6):1185\u20131192."},{"key":"b27","series-title":"OncoTargets Ther","first-page":"955","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis","volume":"11","author":"Sacdalan DB","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. OncoTargets Ther. 2018;11:955\u2013965."},{"issue":"1","key":"b28","series-title":"Nat Commun","first-page":"729","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero C","year":"2021","unstructured":"Valero C, Lee M, Hoen D,  Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12(1):729."},{"issue":"19","key":"b29","series-title":"JCI Insight","first-page":"e59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients","volume":"3","author":"Osa A","year":"2018","unstructured":"Osa A, Uenami T, Koyama S,  Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3(19):e59125."},{"issue":"6","key":"b30","series-title":"J Neurosurg","first-page":"1646","article-title":"Single- versus 2-session Gamma Knife surgery for symptomatic midsize brain metastases: a propensity score-matched analysis","volume":"133","author":"Yomo S","year":"2019","unstructured":"Yomo S, Oda K, Oguchi K. Single- versus 2-session Gamma Knife surgery for symptomatic midsize brain metastases: a propensity score-matched analysis. J Neurosurg. 2019;133(6):1646\u20131654."},{"issue":"6","key":"b31","series-title":"Lancet Oncol","first-page":"e270","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin NU","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H,  Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270\u2013e278."},{"issue":"6","key":"b32","series-title":"Commun Stat Simul Comput","first-page":"1228","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin PC","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228\u20131234."},{"issue":"18","key":"b33","series-title":"Cancer Res","first-page":"4557","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw DC","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u20134566."},{"issue":"6","key":"b34","series-title":"Cancer Immunol Immunother","first-page":"751","article-title":"Tumor microenvironment and lymphocyte infiltration","volume":"61","author":"Rahir G","year":"2012","unstructured":"Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother. 2012;61(6):751\u2013759."},{"issue":"11","key":"b35","series-title":"Nat Rev Immunol","first-page":"651","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman AD","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u2013668."},{"issue":"7745","key":"b36","series-title":"Nature","first-page":"553","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba BM","year":"2019","unstructured":"Szczerba BM, Castro-Giner F, Vetter M,  Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566(7745):553\u2013557."},{"issue":"10","key":"b37","series-title":"Nat Rev Clin Oncol","first-page":"601","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul ME","year":"2019","unstructured":"Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601\u2013620."},{"issue":"10","key":"b38","series-title":"J Cancer Res Clin Oncol","first-page":"2541","article-title":"Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers","volume":"145","author":"Li M","year":"2019","unstructured":"Li M, Spakowicz D, Burkart J,  Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol. 2019;145(10):2541\u20132546."},{"key":"b39","series-title":"Sci Rep","first-page":"12493","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis","volume":"5","author":"Gu XB","year":"2015","unstructured":"Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015;5:12493."},{"issue":"17","key":"b40","series-title":"Cancer Med","first-page":"5983","article-title":"The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: a systematic review and meta-analysis","volume":"10","author":"Naszai M","year":"2021","unstructured":"Naszai M, Kurjan A, Maughan TS. The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: a systematic review and meta-analysis. Cancer Med. 2021;10(17):5983\u20135997."},{"issue":"4","key":"b41","series-title":"Int J Radiat Oncol Biol Phys","first-page":"812","article-title":"Estimating survival in melanoma patients with brain metastases: an update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)","volume":"99","author":"Sperduto PW","year":"2017","unstructured":"Sperduto PW, Jiang W, Brown PD,  Estimating survival in melanoma patients with brain metastases: an update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys. 2017;99(4):812\u2013816."},{"issue":"6","key":"b42","series-title":"JAMA Oncol","first-page":"827","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)","volume":"3","author":"Sperduto PW","year":"2017","unstructured":"Sperduto PW, Yang TJ, Beal K,  Estimating survival in patients with lung cancer and brain metastases: an update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827\u2013831."},{"issue":"2","key":"b43","series-title":"Int J Radiat Oncol Biol Phys","first-page":"334","article-title":"Beyond an updated Graded Prognostic Assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today","volume":"107","author":"Sperduto PW","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J,  Beyond an updated Graded Prognostic Assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol Phys. 2020;107(2):334\u2013343."},{"issue":"1","key":"b44","series-title":"Int J Radiat Oncol Biol Phys","first-page":"60","article-title":"Graded Prognostic Assessment (GPA) for patients with lung cancer and brain metastases: initial report of the small cell lung cancer GPA and update of the non-small cell lung cancer GPA including the effect of programmed death ligand 1 and other prognostic factors","volume":"114","author":"Sperduto PW","year":"2022","unstructured":"Sperduto PW, De B, Li J,  Graded Prognostic Assessment (GPA) for patients with lung cancer and brain metastases: initial report of the small cell lung cancer GPA and update of the non-small cell lung cancer GPA including the effect of programmed death ligand 1 and other prognostic factors. Int J Radiat Oncol Biol Phys. 2022;114(1):60\u201374."},{"issue":"3","key":"b45","series-title":"Cancers (Basel)","first-page":"546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli F","year":"2020","unstructured":"Petrelli F, Signorelli D, Ghidini M,  Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2020;12(3):546."},{"issue":"8","key":"b46","series-title":"Neuro Oncol","first-page":"1261","article-title":"The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis","volume":"23","author":"Jessurun CAC","year":"2021","unstructured":"Jessurun CAC, Hulsbergen AFC, de Wit AE,  The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. Neuro Oncol. 2021;23(8):1261\u20131272."}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/aop\/article-10.3171-2024.5.JNS24259\/article-10.3171-2024.5.JNS24259.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/aop\/article-10.3171-2024.5.JNS24259\/article-10.3171-2024.5.JNS24259.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/aop\/article-10.3171-2024.5.JNS24259\/article-10.3171-2024.5.JNS24259.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T01:19:22Z","timestamp":1738372762000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/aop\/article-10.3171-2024.5.JNS24259\/article-10.3171-2024.5.JNS24259.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":46,"URL":"https:\/\/doi.org\/10.3171\/2024.5.jns24259","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}